Bharat Biotech slashes malaria vaccine price on GAVI-backed pact with UNICEF
Bharat Biotech is reducing the price of its malaria vaccine, Mosqivac, by 40% following a Gavi-backed agreement with UNICEF. The deal aims to make the vaccine more affordable and accessible, potentially reaching one million more children by 2029.
Why it matters
This price reduction is a significant development in global public health, aiming to improve equitable access to life-saving immunizations in developing regions.
Bharat Biotech slashes malaria vaccine price on GAVI-backed pact with UNICEF HYDERABAD Vaccine maker Bharat Biotech International on Friday said it is reducing the price of malaria vaccine Mosqivac by about 40% following an agreement executed by UNICEF and financially backed by Gavi, the Vaccine Alliance. Enabled through an advance payment by the International Finance Facility for Immunisation (IFFIm), the agreement will bring the price of the vaccine to € 5.50 per dose, a reduction of approximately 40 per cent compared to current price of € 9.30. The lower price is expected to take effect by early 2027 and reflects the sustained efforts to shape a more sustainable and competitive malaria vaccine market, Bharat Biotech said announcing the agreement for equitable pricing for the vaccine.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in